Personalized mRNA Vaccines Face Funding Threats Despite Cancer Breakthroughs > 공지사항

• 목록

Personalized mRNA cancer vaccines — crafted to match a patient’s unique tumor mutations — are showing real promise in early trials, especially when paired with immune checkpoint drugs. In one pancreatic cancer trial, several patients remain cancer-free years later. Over 50 clinical trials are now underway. But this breakthrough faces a serious threat: steep declines in U.S. federal funding. Cuts to NIH and National Cancer Institute support, plus political resistance, could derail progress on this potentially game-changing technology. Without sustained investment, its full promise may never be realized. (Scientific American, November 18, 2025)

Personalized mRNA Vaccines Will Revolutionize Cancer Treatment—If Federal Funding Cuts Don’t Doom Them | Scientific American